R & D-a phase I trial of the safety and immunogenicity of a DNA plasmid based vaccine (WOKVAC) encoding epitopes derived from three breast cancer antigens (igfbp-2, HER2, and IGF-IR) in patients…
Ended Awarded Last action
- Contract number
- HHSN26100006
- Awardee
-
University Of Wisconsin System UEI LCLSJAGTNZQ7 Part of University Of Wisconsin System
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $1,214,305
Award facts
- Opportunity
-
- N01CN0501469 Solicitation number
- Cancer Prevention Agent Development Program: Early Phase Clinical Research Award Notice · Posted Mar 4, 2011
- Contract value 100% obligated
- $1,214,304.57 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541712 Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 3 offers Multiple Award, Fair Opportunity
- Pricing
- Cost No Fee
- Place of performance
- Madison, WI 53792, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Funding Only Action | -$56,166 | |
| Change Order | $0 | |
| Funding Only Action | -$14,691 | |
| Change Order | $0 | |
| Change Order | $0 | |
| Other Administrative Action | $0 | |
| Exercise an Option | $250,081 | |
| Other Administrative Action | $0 | |
| Exercise an Option | $251,615 | |
| Funding Only Action | $55,996 | |
| Original award | $727,469 |
Show all 11
About this award
This is a federal contract award from the National Cancer Institute (NCI), a civilian agency within the U.S. government, to the University of Wisconsin System. The $1,214,305 contract is for a Phase I clinical trial to evaluate the safety and immunogenicity of a DNA plasmid-based vaccine (WOKVAC) that targets three breast cancer antigens (IGFBP-2, HER2, and IGF-IR). The contract is part of NCI's Cancer Prevention Agent Development Program, which focuses on early-stage clinical research. The University of Wisconsin System, through its University of Wisconsin - Madison division, is the prime contractor for this contract award. There is no set-aside designation indicated for this contract.
Description
R & D-a phase I trial of the safety and immunogenicity of a DNA plasmid based vaccine (WOKVAC) encoding epitopes derived from three breast cancer antigens (igfbp-2, HER2, and IGF-IR) in patients with breast cancer
Quick answers
Who was awarded contract HHSN26100006?
HHSN26100006 was awarded to University Of Wisconsin System by National Cancer Institute (National Institutes of Health) on July 1, 2015.
How much is contract HHSN26100006 worth?
The government has obligated $1,214,305 on HHSN26100006.
Is contract HHSN26100006 an order under another contract?
Yes. HHSN26100006 is a delivery order under HHSN261201200033I, an indefinite delivery contract, on Cancer Prevention Agent Development Program 2012-2017.
Was contract HHSN26100006 competed?
The extent of competition for HHSN26100006 was full and open competition. The government received 3 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award